Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 12

JAK Inhibitor Selectivity and Dose-Related Toxicity

Published on: September 12, 2024

Gordon Lam, MD, Leonard Calabrese, DO, Grace Wright, MD, PhD, Jeffrey A. Sparks, MD, MMSc, Catherine Bakewell, MD

Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.

EP. 1: Intro and Welcomes

EP. 2: Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP. 3: Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP. 4: Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP. 5: Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP. 6: Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP. 7: Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP. 8: Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

EP. 9: Advanced Treatment Options for RA: Exploring the Data

EP. 10: Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP. 11: JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

Now Viewing

EP. 12: JAK Inhibitor Selectivity and Dose-Related Toxicity

Video content above is prompted by the following:

Mechanism of action also differs in the Janus kinase (JAK) inhibitor class. Tofacitinib inhibits JAK1/JAK2/JAK3, baricitinib inhibits JAK1/JAK2, and upadacitinib inhibits JAK1. Can you describe how more specific selectivity of JAK inhibition influences dose-related toxicity?